This Article Full Text Full Text (PDF) Data Supplement Data Supplement All Versions of this Article: 117/5/629    most recent CIRCULATIONAHA.107.723262v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kim, R. J. Search for Related Content PubMed PubMed Citation Articles by Kim, R. J. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Heart Attack MRI Scans Related Collections CT and MRI Related Article

(Circulation. 2008;117:629-637.)
© 2008 American Heart Association, Inc.

Imaging

Performance of Delayed-Enhancement Magnetic Resonance Imaging With Gadoversetamide Contrast for the Detection and Assessment of Myocardial Infarction

An International, Multicenter, Double-Blinded, Randomized Trial

Raymond J. Kim, MD; Timothy S.E. Albert, MD; James H. Wible, PhD; Michael D. Elliott, MD; John C. Allen, PhD; Jennifer C. Lee, PhD; Michele Parker, RN, MS; Alicia Napoli, BS; Robert M. Judd, PhD, for the Gadoversetamide Myocardial Infarction Imaging Investigators

From the Duke Cardiovascular Magnetic Resonance Center, Durham, NC (R.J.K., T.S.E.A., M.D.E., M.P., R.M.J.), and Tyco Healthcare/Mallinckrodt, Inc, Hazelwood, Mo (J.H.W., J.C.A., J.C.L., A.N.).

Correspondence to Raymond J. Kim, MD, Duke Cardiovascular MRI Center, DUMC-3934, Durham, NC 27710. E-mail Raymond.Kim{at}duke.edu

Received June 21, 2007; accepted November 5, 2007.

Background— The identification and assessment of myocardial infarction (MI) are important for therapeutic and prognostic purposes, yet current recommended diagnostic strategies have significant limitations. We prospectively tested the performance of delayed-enhancement magnetic resonance imaging (MRI) with gadolinium-based contrast for the detection of MI in an international, multicenter trial.

Methods and Results— Patients with their first MI were enrolled in an acute (16 days after MI; n=282) or chronic (17 days to 6 months; n=284) arm and then randomized to 1 of 4 doses of gadoversetamide: 0.05, 0.1, 0.2, or 0.3 mmol/kg. Standard delayed-enhancement MRI was performed before contrast (control) and 10 and 30 minutes after gadoversetamide. For blinded analysis, precontrast and postcontrast MRIs were randomized and then scored for enhanced regions by 3 independent readers not associated with the study. The infarct-related artery perfusion territory was scored from x-ray angiograms separately. In total, 566 scans were performed in 26 centers using commercially available scanners from all major US/European vendors. All scans were included in the analysis. The sensitivity of MRI for detecting MI increased with rising dose of gadoversetamide (P<0.0001), reaching 99% (acute) and 94% (chronic) after contrast compared with 11% before contrast. Likewise, the accuracy of MRI for identifying MI location (compared with infarct-related artery perfusion territory) increased with rising dose of gadoversetamide (P<0.0001), reaching 99% (acute) and 91% (chronic) after contrast compared with 9% before contrast. For gadoversetamide doses 0.2 mmol/kg, 10- and 30-minute images provided equal performance, and peak creatine kinase-MB levels correlated with MRI infarct size (P<0.0001).

Conclusions— Gadoversetamide-enhanced MRI using doses of 0.2 mmol/kg is effective in the detection and assessment of both acute and chronic MI. This study represents the first multicenter trial designed to evaluate an imaging approach for detecting MI.

---

 

CLINICAL PERSPECTIVE

Related Article:

Clinical Summaries
Circulation 2008 117: 589-591. [Extract] [Full Text]

This article has been cited by other articles:

				M. R. Patel, P. J. Cawley, J. F. Heitner, I. Klem, M. A. Parker, W. A. Jaroudi, T. J. Meine, J. B. White, M. D. Elliott, H. W. Kim, et al. Detection of Myocardial Damage in Patients With Sarcoidosis Circulation, November 17, 2009; 120(20): 1969 - 1977. [Abstract] [Full Text] [PDF]

				S. Achenbach, V. Dilsizian, C. M. Kramer, and W. A. Zoghbi The Year in Coronary Artery Disease J. Am. Coll. Cardiol. Img., June 1, 2009; 2(6): 774 - 786. [Abstract] [Full Text] [PDF]

				K. H. Schuleri, M. Centola, R. T. George, L. C. Amado, K. S. Evers, K. Kitagawa, A. L. Vavere, R. Evers, J. M. Hare, C. Cox, et al. Characterization of peri-infarct zone heterogeneity by contrast-enhanced multidetector computed tomography: a comparison with magnetic resonance imaging. J. Am. Coll. Cardiol., May 5, 2009; 53(18): 1699 - 1707. [Abstract] [Full Text] [PDF]

				L. Axel MRI of the Microarchitecture of Myocardial Infarction: Are We Seeing New Kinds of Structures? Circ Cardiovasc Imaging, May 1, 2009; 2(3): 169 - 170. [Full Text] [PDF]

				R. J. Gibbons, P. A. Araoz, and E. E. Williamson The year in cardiac imaging. J. Am. Coll. Cardiol., January 6, 2009; 53(1): 54 - 70. [Full Text] [PDF]

				P. W Armstrong Defining myocardial infarction: a work in progress Heart, August 1, 2008; 94(8): 1076 - 1079. [Full Text] [PDF]

				H. Thiele, K. Schindler, J. Friedenberger, I. Eitel, G. Furnau, E. Grebe, S. Erbs, A. Linke, S. Mobius-Winkler, D. Kivelitz, et al. Intracoronary Compared With Intravenous Bolus Abciximab Application in Patients With ST-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: The Randomized Leipzig Immediate Percutaneous Coronary Intervention Abciximab IV Versus IC in ST-Elevation Myocardial Infarction Trial Circulation, July 1, 2008; 118(1): 49 - 57. [Abstract] [Full Text] [PDF]